This page shows the latest pegpleranib news and features for those working in and with pharma, biotech and healthcare.
Those only gathered pace after a late-stage setback for age-related macular degeneration (AMD) therapy Fovista (pegpleranib), which was licensed by the company in 2014 in a deal valued at
Novartis' hopes of positioning pegpleranib as a duo alongside its big-selling age-related macular degeneration (AMD) drug Lucentis have been dashed. ... The key message from the data is that the proven efficacy of Lucentis monotherapy was not improved by
These include RLX030 (serelaxin) for acute heart failure, Fovista (pegpleranib) and RTH258 (brolucizumab) for neovascular age-related macular degeneration (AMD), and novel migraine prevention drug AMG334.
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...